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S U M M A R Y
Background: Artemisinin derivatives are the mainstay of antimalarial treatment, both for uncomplicated
malaria and for severe disease. Artemisinins are known for their rapid onset of action, good tolerability,
and safety. However, besides the sporadic but worrying reports of delayed parasite clearance after
treatment with artemisinins, there have been an increasing number of reports of acute haemolytic
anaemia following their use and the safety of this class of antimalarials is being questioned.
Methods: In this systematic review, all reports of patients experiencing haemolysis following the use of
artemisinins for the treatment of malaria were identiﬁed and collated into an electronic database.
Summary statistics were calculated to characterize the epidemiology and clinical features of this safety
concern related to artemisinin derivatives.
Results: A total of 37 patients were identiﬁed suffering from haemolysis following the treatment of severe
malaria with artemisinin derivatives. Thirty-one cases had received intravenous artesunate, while the
remaining cases were attributed to other parenteral or oral regimens of artemisinin derivatives. The
majority of patients were returning travellers (n = 30), and six clinical cases had been reported in paediatric
patients. The median onset of haemolysis was 15 (interquartile range (IQR) 13–15) days after the initiation
of treatment for the ‘delayed-onset’ pattern and 17 (IQR 13–22) days for the ‘persistent’ haemolysis pattern.
The median reduction in haemoglobin due to haemolysis was 6 g/dl (IQR 4–8 g/dl). The estimated
proportion of patients suffering from severe malaria experiencing haemolysis after treatment with
artemisinin derivatives was 13% (95% conﬁdence interval 9–18%), and 73% of these (i.e., 9% of the total
population) required blood transfusions. No fatal outcome has been reported in the literature to date.
Conclusions: Haemolysis is commonly associated with the class of artemisinin drugs when used for the
treatment of severe malaria. Potential causes of this safety issue are discussed. Although no deaths
attributed to haemolysis have been reported so far, this safety issue may lead to life-threatening anaemia
and is particularly worrying for regions where safe blood products are not readily available.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-SA license (http://creativecommons.org/licenses/by-
nc-sa/3.0/).
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Despite recent progress in rolling back malaria-related mor-
bidity and mortality, the burden of disease remains unacceptably
high with an estimated 207 million clinical cases of malaria each
year and more than 600 000 malaria-related deaths.1 Severe
malaria therefore remains a serious clinical condition with
considerable mortality, even in high-income regions.2
The artemisinin class of antimalarials following the spread of
drug resistance in Plasmodium falciparum isolates to previously used* Corresponding author. Tel.: +43 1 40400 44400; fax: +43 1 40400 44180.
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1201-9712/ 2014 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-sa/3.0/).ﬁrst-line drugs.3 Artemisinins were demonstrated to show unparal-
leled rapid parasite clearance, excellent tolerability, and were
assumed to be exceptionally safe in the treatment of malaria.4,5 Due
to a high rate of recrudescence when used as monotherapy, the use
of artemisinins has been recommended in combination with partner
drugs for the treatment of uncomplicated malaria, in the form of
artemisinin combination therapies (ACT).6–8 Artesunate, arte-
mether, and dihydroartemisinin became the most widely employed
oral artemisinin derivatives used in ACT.
The intravenous administration of artesunate – a water soluble
artemisinin derivative readily hydrolysed to the active metabolite
dihydroartemisinin – was demonstrated to lead to improved
survival rates compared to standard quinine therapy for severeciety for Infectious Diseases. This is an open access article under the CC BY-NC-SA
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Figure 1. Identiﬁcation of clinical reports of haemolysis associated with the use of
artemisinins.
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adult Asian patient population, as well as for African children.9,10
Parenteral artesunate became the treatment of choice for severe P.
falciparum malaria based on these clinical trials.11 Besides its
efﬁcacy, it was postulated that intravenous artesunate showed
good tolerability and superior safety compared to the previous
standard drug quinine.
Until recently, the rare occurrence of hypersensitivity reactions
was considered the only clinically important safety issue
associated with artemisinins. However, since then, the publication
of an increasing number of cases and case series of patients
experiencing late onset haemolysis following antimalarial treat-
ment with artemisinin derivatives has raised important questions
about the safety of this class of antimalarials.12–19 To date,
conclusive evidence about the frequency, clinical implications,
pathophysiology, and importance of haemolysis associated with
the use of artemisinin derivatives has been lacking. In this
systematic review we collate all the available evidence to address
these questions and to provide the basis for further discussions on
the impact of this ﬁnding on our current management of patients
with severe P. falciparum malaria.
2. Methods
In this systematic review, all reported cases of late onset
haemolysis following treatment with artemisinin derivatives were
identiﬁed. Published reports were sought using the following search
terms: ‘artemisinin’, ‘artesunate’, and ‘artemether’ combined with
one of the following keywords: ‘haemolysis’, ‘delayed haemolysis’,
‘anaemia’, and ‘haemolytic anaemia’. Medline, Thomson Reuters
Web of Science, Google Scholar, and conference abstracts were
screened to identify further publications. The unpublished grey
literature was searched using internet search engines, interviews of
experts in the ﬁeld, and references of published reports. There was
no exclusion on the basis of time period or language of publication.
All studies were assessed for risk of bias based on study design and
the reporting of outcome variables. Data were entered into an
electronic database for further analysis.
3. Deﬁnitions
‘Returning traveller’ was deﬁned as anyone native to a non-
malaria endemic region, visiting an endemic region and returning
from there to his/her native non-endemic region. Consequently, a
Nigerian man who was diagnosed and treated in Japan was not
classiﬁed as a returning traveller as he was a native of an endemic
region.15 ‘Haemolysis’ is the destruction of red cells with subsequent
release of haemoglobin. Published studies did not use uniform
deﬁnitions for haemolysis. In this study, haemolysis associated with
the use of artemisinin derivatives was therefore deﬁned as the onset
of haemolysis evidenced by a decrease in haemoglobin and an
increase in lactate dehydrogenase (LDH) after the complete
clearance of asexual parasitaemia from peripheral blood.
Two distinct patterns of haemolysis after the use of artemisinin
therapy have been described and classiﬁed. These encompass a
delayed onset and a persistent pattern of haemolysis
(Figure 1).14,16–19 ‘Delayed haemolysis’ was deﬁned as the
occurrence of a decrease in haemoglobin associated with low
haptoglobin or increased LDH at >7 days following the initiation of
artemisinin treatment.19 ‘Persistent haemolysis’ was deﬁned as
continuing haemolysis starting from or around day 7 of artemi-
sinin treatment and persisting beyond day 14. ‘Severe malaria’ was
deﬁned by the authors of the published reports in accordance with
the World Health Organization (WHO) recommendations,20 a
modiﬁcation of this as summarized in the German national
guidelines,13 or based on a deﬁnition used by the ‘Severe Malaria inAfrican Children Network’ (SMAC).19 Data were extracted by the
investigators from the original reports and were entered into a
purpose built database. The statistical analysis encompassed
descriptive statistics (JMP 10.0; SAS Institute, NC, USA). Median
and interquartile ranges were used to describe distributions.
4. Results
A total of 11 published studies and one poster presentation
reporting artemisinin-associated haemolysis were identiﬁed and
included in this review.12–19,21–24 One study was excluded from
further analysis,12 since the reported patients were part of a second
publication, which was used for the purpose of this systematic
review.13 In addition to the above-mentioned scientiﬁc papers,
reports by the Centers for Disease Control and Prevention (CDC,
Atlanta, USA)25 and by the Medicines for Malaria Venture (Geneva,
Switzerland) were identiﬁed and included in this analysis26
(Figure 1). All published cases were reported from non-malaria
endemic regions except for one paper investigating paediatric
patients in Africa.19 Details of patient characteristics, the treatment
given, and laboratory ﬁndings are summarized in the Supplemen-
tary Material (Supplementary File 1).
4.1. Description of study characteristics
A total of 37 cases of haemolysis associated with the use of
artemisinin derivatives in the treatment of malaria have been
reported so far.12–19,21,23,24,26 Thirty-three cases have been
published in research papers and four cases are referred to in a
meeting report (one from China, one from the USA, and two from
Canada).26 In addition, surveillance data from France were
discussed in that report but have not yet been published and
were therefore not available for the purpose of this review. The
reports are mainly retrospective studies (n = 5) and case reports
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important prospective study was conducted in Africa and
investigated 72 Gabonese and Ghanaian children for the potential
occurrence of artemisinin-associated haemolysis.19
4.2. Description of the patient population
Fifteen patients were female and 16 were male; information on
gender was not available for six patients. The median age of
patients was 45 years (n = 33; interquartile range (IQR) 25–54
years); the youngest was a 6-month-old child and the oldest was a
78-year-old returning traveller. No information on age was
available for four cases. The majority of reported cases (n = 31)
were returning travellers, including 30 adults and one child
(median age 49, IQR 32–54, range 5–78 years). Among these,
24 attended health care institutions in Europe, three in Japan, two
in Canada, and one in China.
To date, six paediatric cases of artemisinin-associated haemo-
lysis have been published.18,19 Five were Africans treated at local
health care centres in Gabon and Ghana,19 and one child received
treatment in Europe.18 All children were treated with intravenous
artesunate and received artemether–lumefantrine as follow-on
treatment. The median age of paediatric patients was 24 months
(IQR 10–60 months, range 6–60 months).
4.3. Description of treatment modality and artemisinin derivatives
Clinical reports encompassed the use of several different
artemisinin derivatives and modes of administration. The majority
of patients experiencing haemolysis after the administration of
artemisinin therapy were treated with intravenous artesunate. Out
of a total of 37 cases, 31 developed haemolysis following treatment
with intravenous artesunate (Table 1). Two returning travellers –
one reported from China and one from the UK – experienced
haemolysis after the administration of intramuscular arte-
mether.21,26 Intra-rectal administration of artesunate was similarly
associated with haemolysis in two case reports, and both patients
were also treated with quinine–clindamycin.13 Finally, two adult
patients experiencing late onset haemolysis following the use of oral
ACTs were reported from Italy.23,24 One of these patients was HIV-
positive and was treated with intravenous quinine before receiving
artemether–lumefantrine as follow-on treatment.24
4.4. Description of pharmaceutical products
The majority of clinical cases of haemolysis following the use of
artemisinin derivatives involved intravenous artesunate. Interest-
ingly, the pharmaceutical product in use for all except three casesTable 1
Region and study type categorization of cases
Region Retrospective Prospective
Adults Children Adults Children
Europe 15 (IV)a 1 (IV) 3 (IV) 0
2 (oral)b
2 (IR)c
1 (IM)d
Africa 0 0 0 5 (IV)
Asia (Japan) 4 (IV) 0 0 0
USA and Canada 3 (IV) 0 0 0
China 1 (IM) 0 0 0
Total 28 1 3 5
IV, intravenous; IM, intramuscular.
a IV: intravenous artesunate.
b Oral: oral artemether–lumefantrine.
c IR: intra-rectal artesunate.
d IM: intramuscular artemether.was manufactured by the Chinese company Guilin Pharma, which
is the main global supplier of intravenous artesunate preparations.
A CDC evaluation reported no case of haemolysis after the use of
intravenous artesunate preparations produced under strict good
manufacturing practice (GMP) conditions by the US Army Medical
Material Development Activity in 2013, including a study in
197 African children with severe malaria treated with GMP-
compliant intravenous artesunate.25,27 However, Bryan et al.
subsequently identiﬁed one case of artemisinin-associated hae-
molysis in the USA and two cases in Canada, both following the use
of the GMP-compliant drug formulation.26 Both cases of haemo-
lysis associated with the use of oral artemether–lumefantrine
involved a GMP-compliant product from Novartis.23,24 Intra-rectal
artesunate preparations were produced by Mepha, Switzerland,13
and no further information was available for the intramuscular
artemether drugs.21,26
4.5. Description of timing, pattern, and impact of haemolysis
associated with artemisinin use
The onset and duration of haemolysis after the administration
of artemisinin derivatives was categorized into the two main
patterns of ‘delayed’ and ‘persistent’ haemolysis, with some cases
not falling into either of these categories and termed ‘complex
pattern’ (Figure 2 and Table 2).
Among all published patient reports, information for further
classiﬁcation was available for 26 cases (n = 23 for intravenous
artesunate, n = 1 for intramuscular artemether, n = 2 for oralSudden reduction of  haemoglobin  around second  week post-t reatme nt. 
Wk 
Hb
Persistent haem olysis  and  failure  of recovery of haem oglo bin po st-
treatment.
Persistent
Figure 2. Patterns of haemolysis associated with the use of artemisinin drugs.
Table 2
Pattern of haemolysis with respective artemisinin derivatives and routes of
administration
Pattern of
haemolysis
IV
artesunate
IR
artesunate
IM
artemether
Oral
artemether–
lumefantrine
Delayed 15 0 1 1
Persistent 8 0 0 1
Limited or no
information
availablea
8 2 1 0
Total 31 2 2 2
IV, intravenous; IR, intra-rectal; IM, intramuscular.
a The information was not sufﬁcient to classify it as a recurrent or persistent
haemolysis pattern or even as a complex pattern.
Table 3
Intravenous artesunate dosage received by patients
Intravenous artesunate: cumulative dosage (mg/kg) Number of cases
7.5 7
8 1
9 2
9.6 2
12 10
19.2 1
Unkown 8
Total 31
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artesunate group displayed a delayed pattern of haemoly-
sis,13,14,17–19 and eight showed persistent haemolysis16
(Table 2). The patient treated with intramuscular artemether
was classiﬁed as experiencing delayed haemolysis.
Among the two patients with oral artemether–lumefantrine
use, one patient showed signs of delayed haemolysis and the other
persistent haemolysis.23,24
The lowest haemoglobin levels in the delayed haemolysis group
occurred at a median 15 days post-treatment initiation (n = 14; IQR
13–15, range 8–30 days). Four cases had the lowest haemoglobin
before 2 weeks (days 8, 9, 10, and 11).15,18,22,23,26 Another case had
two nadirs (oral artemether–lumefantrine), on days 8 and 22,
respectively.23 Patients in the persistent haemolysis group showed
varying reductions in haemoglobin with a nadir at a median day 17
(n = 6; IQR 13–22, range 13–32 days). The median reduction in
haemoglobin concentration compared to baseline was 6 g/dl
(n = 19; IQR 3.6–8.1, range 1.5–9.8 g/dl). Other reported markers
of haemolysis included haptoglobin and LDH.
4.6. Estimates of frequency of haemolysis and severe haemolysis after
the therapeutic use of artemisinins
The majority of published reports are case reports and case
series and, as a result of this study design, no conclusion about the
potential frequency of haemolysis could be drawn from these
reports. Therefore only a subset of studies including retrospective
cohort studies (n = 4)13,14,17,18 and prospective studies (n = 1)19
were used to estimate the frequency of haemolysis following
treatment with artemisinin antimalarials.
Signs of haemolysis associated with artemisinin treatment
were evident in 24 of a total of 192 treated patients (13%; 95%
conﬁdence interval (CI) 9–18%). These patients were African
children (n = 5) and returning travellers (n = 19). Importantly,
11 patients among 15 with information about the use of blood
products experienced haemolysis severe enough to necessitate the
use of blood transfusions (73%; 95% CI 48–89%). Consequently, 9%
(95% CI 6–14%) of the total patient population suffering from
severe malaria and treated with artemisinin derivatives required
blood transfusions late haemolysis.
4.7. Description of the total dose of artemisinins in clinical cases of
haemolysis
The total dose of artemisinin derivatives administered in the
reported cases was reviewed for potential association with this
safety concern. For intravenous artesunate, the median dose
administered to patients (n = 23) was 9.6 mg/kg bodyweight (IQR
7.5–12, range 7.5–19.2 mg/kg). Details of intravenous artesunate
received by these patients are summarized in Table 3. Intra-rectalartemether was administered at a total dose of 200 mg per dose,
administered ﬁve times. Finally, oral artemether–lumefantrine
was administered at 20/120 mg of artemether–lumefantrine twice
daily for 3 days. Total doses of artemisinin treatment are depicted
in Table 3 and may add up to 20 mg/kg when considering follow-on
therapy.
Several patients reported in this context had received oral ACTs
or other antimalarials following parenteral treatment with
artemisinins. Out of 31 cases who received intravenous artesunate
as antimalarial therapy, 12 received follow-on treatment with
artemether–lumefantrine, atovaquone–proguanil (n = 6), or mef-
loquine (n = 1). Six cases did not receive any further antimalarials
and for eight cases no information was available.
4.8. Analysis of potential co-variables associated with the risk of late
onset haemolysis following treatment with artemisinin derivatives
Age and parasitaemia were both associated with the risk of the
occurrence of late onset haemolysis in the prospective clinical
study in African children.19 Geometric mean parasitaemia was
92 642 (66 456–129 159)/ml blood in those without haemolysis
and 306 968 (199 825–471 512)/ml blood in those with evidence of
haemolysis. To further investigate the association of parasitaemia
with the occurrence of haemolysis, median parasitaemia was
calculated for all reported cases in the published literature. This
analysis showed a median parasitaemia of 13% (IQR 7–29%) in all
patients experiencing haemolysis following the treatment of
severe malaria with artemisinin derivatives.
5. Discussion
Following initial case reports of returning travellers experienc-
ing artemisinin-associated haemolysis, reports from several
independent groups in different endemic and non-endemic
countries have substantiated the description of this phenome-
non.12–19,21,24 Current estimates stemming from cohort studies
indicate that haemolysis may occur in an estimated 13% of all
patients treated with artemisinin derivatives for severe P.
falciparum malaria.13,14,17,18
Importantly, haemolysis occurred in all patient populations
including adult and paediatric patients, returning travellers and
individuals residing in malaria endemic regions, and patients of
both sexes.13,15–19,21–24,26,28 The observation of a predominantly
adult patient population in returning travellers may be due to
better follow-up in this patient population rather than to
differences in the risk for this safety concern.
The absolute reduction in haemoglobin due to late onset
haemolysis is of great clinical importance. A median reduction of
6 g/dl is an important medical event and may indeed become life-
threatening in the absence of readily available blood transfusions.
Importantly, the onset of haemolysis in the second to third week
post-treatment initiation makes it most likely to occur – in the case
of an uneventful recovery – when patients have already been
discharged from hospital. Active screening for this complication
K. Rehman et al. / International Journal of Infectious Diseases 29 (2014) 268–273272therefore appears essential, and a better identiﬁcation of patients
most at risk of haemolysis would constitute major progress in the
future management of severe malaria.
Interestingly, late onset haemolysis following treatment with
artemisinins does not present with a uniform pattern or timing.
Whereas the majority of patients in this review experienced
delayed onset of haemolysis after initial cessation of malaria-
associated haemolysis,13,14,17–19 a sub-set of patients clearly
showed prolonged and continuous haemolysis.16–19 It is currently
unclear whether these two clinical presentations represent distinct
pathophysiological conditions or whether they constitute
extremes of a spectrum of clinical presentations. The retrospective
nature of the majority of publications and a lack of standardization
of the deﬁnition of late onset haemolysis employed in the
respective case reports and case series, further add to the
complexity of this assessment and are limitations of our analysis.
The adoption of a strict case deﬁnition as employed in the
prospective study in African children is therefore necessary and
should be employed in future clinical reports and prospective
studies on this topic. In addition, a number of other potential
reasons for haemolysis, including blood transfusion-related
haemolysis or haemolysis induced by concomitant medication,
may further blur our understanding of this phenomenon. A
uniform case deﬁnition and complete reporting of clinical data will
therefore allow comparison of data and will assist in disentangling
potential confounding factors.
5.1. Hypotheses for the underlying pathophysiology of artemisinin-
associated haemolysis
Currently there are a number of potential pathophysiological
mechanisms to explain the phenomenon under discussion
(Table 4). To date, and based on the features of published cases,
several of these proposed hypotheses can be refuted as the main
underlying reason. Firstly, late onset haemolysis has predomi-
nantly been described after the use of intravenous artesunate, but
it is deﬁnitely not restricted to the use of parenteral artesunate,
since case reports have been published for both intramuscular
artemether as well as for oral artemether–lumefantrine when used
for the treatment of severe malaria.21,23,24,26 It must therefore be
assumed that late onset haemolysis is a class phenomenon of allTable 4
Potential causes of haemolysis following the treatment of severe malaria with artemis
Hypothesis Comment 
Restricted to special patient populations (e.g., returning
travellers or adult patients)
Cases have been reporte
well as in African childr
Late toxicity due to a manufacturing problem of a single
producer
Cases have been reported
well as for a GMP-compl
been reported following
artemether–lumefantrin
Exclusively associated with parenteral use of artemisinin
derivatives
Cases have been reporte
used for the treatment o
Direct suppressive effect of artemisinins on bone marrow.
Total dose is increased due to follow-on treatment of
IV artesunate with oral ACT
Reticulocyte counts are c
capacity of the bone ma
doses of artesunate and
Auto-immune-mediated haemolysis triggered by the use
of artemisinin derivatives
Coombs testing has been
of haemolysis without t
Differences in pharmacokinetics based on metabolism,
drug transporters, and other host factors
Artemisinins have a sho
inconsistent with the la
experimental evidence t
G6PD deﬁciency, other haemoglobinopathies, or enzyme
defects and other host factors
G6PD deﬁciency has bee
haemoglobinopathies an
Consequence of synchronous decomposition of previously
parasitized erythrocytes (‘pitted erythrocytes’)
Available experimental e
unclear why haemolysis
IV, intravenous; GMP, good manufacturing practice; EMA, European Medicines Agency; artemisinin derivatives and all routes of administration. It is also
evident that haemolysis may occur following the use of
pharmaceutical products of several global companies, minimizing
the possibility of a manufacturing problem as the sole explanation
for this ﬁnding. Increased reticulocyte counts during haemolysis
contradict the hypothesis of direct bone marrow suppression by
artemisinin drugs. Glucose-6-phosphate dehydrogenase (G6PD)
deﬁciency has repeatedly been ruled out in reported cases,
however other haemoglobinopathies and enzyme deﬁciencies
have not been investigated consistently. Finally, autoimmune
haemolysis is unlikely to serve as the uniform underlying
mechanism since auto-antibodies were detected only in a minority
of clinical cases. Similarly, blackwater fever – a syndrome of
haemolysis, haemoglobinuria, and renal insufﬁciency associated
with the use of quinine treatment – may be discerned from the
reported phenomenon in artemisinin-treated patients based on
the differences in timing of haemolysis.
To date, the feature of hyperparasitaemia at initiation of
treatment remains the most consistent ﬁnding in patients
experiencing late onset haemolysis. As parenteral artesunate is
the treatment of choice for this patient population, this feature
explains the predominance of case reports with delayed haemolysis
associated with intravenous artesunate. This hypothesis is further
supported by the fact that oral artemether–lumefantrine therapy –
an antimalarial used safely on a very large scale in uncomplicated
malaria – may lead to haemolysis when used in hyperparasitaemic
patients. The observation of a much higher proportion of so-called
‘pitted erythrocytes’ following the treatment of patients with
artesunate compared to quinine may therefore provide an attractive
direction for further investigation of the underlying pathophysiolo-
gy of haemolysis.30,31 Pitted erythrocytes have been described as
previously parasitized erythrocytes that have apparently been
cleared from intracellular parasites by a process leaving the
erythrocyte intact and in circulation. It is hypothesized that these
circulating pitted erythrocytes may decompose following a lag
period after the treatment of hyperparasitaemic patients within a
relatively short period of time – potentially due to an invariably
reduced lifespan.32 Although this explanation is appealing for
various reasons, it is currently unable to explain why only a sub-
group of hyperparasitaemic patients will ultimately experience
haemolysis. Additional features including host genetics, druginin derivatives
Conclusion
d both in returning travellers in Europe and Japan, as
en.
Refuted
 for IV artesunate produced by a Chinese company, as
iant preparation from the USA. The occurrence has also
 intra-rectal artesunate by another producer and oral
e produced by a GMP facility with EMA approval.
Refuted
d following the use of artemether–lumefantrine when
f hyperparasitaemic severe malaria patients.
Refuted
onsistently increased indicating adequate production
rrow. Cases have been reported with relatively low
 with non-ACT follow-on therapy.
Refuted
 negative in the majority of cases. Consistent resolution
he use of corticosteroids.
Unlikely to be
the main
underlying mechanism.
A potential explanation
for a subset of patients?
rt plasma half-life of only a few hours, which is
te onset of haemolysis.33,34 There is currently no
o support this hypothesis.
Unlikely
n ruled out in all case reports. Investigations for other
d enzyme defects have not been reported consistently.
Potential explanation
vidence supports this hypothesis. However, it is
 only occurs in a subset of hyperparasitaemic patients.
Potential explanation
ACT, artemisinin combination therapy; G6PD, glucose-6-phosphate dehydrogenase.
K. Rehman et al. / International Journal of Infectious Diseases 29 (2014) 268–273 273metabolism, and synchronicity of P. falciparum infections may play
an important role in this context.33,34 Further research is therefore
needed to improve our understanding of this phenomenon and to
better identify those patients most at risk of this serious safety
concern.
5.2. Implications for clinical practice
Currently, there is uniform agreement that intravenous
artesunate should remain the treatment of choice for severe P.
falciparum malaria based on the survival beneﬁt demonstrated in
prospective randomized controlled clinical trials. The surprising
failure to identify this important safety issue of haemolysis in these
large clinical trials (at least with hindsight) is most likely due to a
rather low mean parasitaemia in both studies (39 850/ml and
47 922/ml for SEAQUAMAT and AQUAMAT, respectively) and to an
effective end of follow-up for most participants in these clinical
trials occurring prior to the median time of onset of haemolysis.
This failure highlights the necessity of conducting state of the art
clinical phase III studies for the registration of GMP-compliant
drugs with stringent international regulatory authorities before
their inclusion in international treatment recommendations. This
was not the case for parenteral artesunate and a repetition of this
failure should be avoided in future drug development studies.
The most important clinical implication of these ﬁndings is
that treating physicians should be instructed of the existence and
nature of this potentially life-threatening late adverse reaction
following the treatment of severe malaria with artemisinin-
containing drugs. It is recommended that patients be informed of
this safety concern and that follow-up visits be attended at least
once weekly for 4–6 weeks. Clinical examinations and haema-
tological assessments, including haemoglobin (and LDH and
haptoglobin wherever possible), should be performed to detect
cases of delayed haemolysis. Currently there is no evidence of a
beneﬁt of once-daily versus twice-daily dosing of artemisinins on
the prevalence of delayed haemolysis. Late onset haemolysis
must be regarded, at the same time, as an adequately
manageable complication in high-resource settings as well as
a serious threat to patient management in resource-constrained
regions lacking adequate logistics for weekly follow-up, repeated
laboratory investigations, and availability of safe blood transfu-
sions. It is this patient population that attracts most of our
attention for the potential clinical implications of artemisinin-
associated haemolysis.
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